Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Optimization of Serum and Microarray Concentrations for a Semiquantitative Multiplex Indirect Immunoassay.

Created on 02 Jul 2025

Authors

Patricia Quaranta, Rocío Paz-González, Selva Riva-Mendoza, Pablo Domínguez-Guerrero, Francisco J Blanco García, Cristina Ruiz-Romero, Lucía Lourido, Valentina Calamia

Published in

Methods in molecular biology (Clifton, N.J.). Volume 2929. Pages 71-81.

Abstract

The versatility of protein microarrays provides a variety of possibilities to explore proteomic profiles, allowing researchers to investigate multiple proteins simultaneously with high efficiency. In this study, we employed xMAP® technology to carry out a multiplex indirect semiquantitative immunoassay using the MILLIPLEXⓇ HCYTAAB-17K kit. This kit is designed with an integrated microarray containing 3 positive controls, 1 negative control, and 14 analytes.In this chapter, we provide a detailed protocol for optimizing the serum conditions required to perform the immunoassay. In addition, we have optimized the commercial microarray itself, focusing on reducing non-specific binding and minimizing false positives. Through these improvements, we aim to increase both the sensitivity and specificity of the assay, ensuring more robust and reproducible results in proteomic profiling. The optimization also helps to extend the usability of the kit, making it more versatile for future experiments.

PMID:
40601144
Bibliographic data and abstract were imported from PubMed on 02 Jul 2025.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 34
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement